Testing PDR-001 for Parkinson's Disease
Part of Brain & nervous system clinical trials.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Parkinson's disease (by standard criteria).
- Your age must be between 40 and 65 years old.
- Your Parkinson's diagnosis must have been made within the last 5 years.
- Your symptoms should be mild to moderate (Hoehn & Yahr stage 2 or less when off medication).
- You cannot have had any prior brain surgery (like deep brain stimulation) or have other brain conditions.
- You must not be on blood thinners or have certain infections (like hepatitis B, C, HIV, or syphilis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet (VG081821AC) for people with early-to-mid-stage Parkinson's disease who have not recently used levodopa. The goal is to see if it can improve movement symptoms safely.
This study follows people with Parkinson's disease over time to understand how the disease progresses and changes. Researchers will collect information about your symptoms, brain health, and overall wellness to help improve future treatments.
This trial tests a new gene therapy called BBM-P002 for Parkinson's disease. It aims to see if the treatment is safe and tolerable, and may help people with moderate to advanced Parkinson's who have had the condition for at least 5 years.
This early-phase trial tests how safe and potentially effective KL002 is for people with advanced Parkinson’s disease. It may help reduce Parkinson’s movement symptoms, but the main early goal is safety.
This trial tests a new injection called UX-DA003 for people with Parkinson's disease whose current medications are becoming less effective. It aims to see if this treatment can help reduce "off" time and improve motor symptoms.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.